173 related articles for article (PubMed ID: 38601319)
1. Redox
Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
[TBL] [Abstract][Full Text] [Related]
2. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
[TBL] [Abstract][Full Text] [Related]
3. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract][Full Text] [Related]
5. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
[TBL] [Abstract][Full Text] [Related]
6. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
Scalera S; Ricciuti B; Mazzotta M; Calonaci N; Alessi JV; Cipriani L; Bon G; Messina B; Lamberti G; Di Federico A; Pecci F; Milite S; Krasniqi E; Barba M; Vici P; Vecchione A; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Buglioni S; Pescarmona E; Sharma B; Felt KD; Lindsay J; Rodig SJ; De Maria R; Caravagna G; Cappuzzo F; Ciliberto G; Awad MM; Maugeri-Saccà M
Ann Oncol; 2023 Mar; 34(3):275-288. PubMed ID: 36526124
[TBL] [Abstract][Full Text] [Related]
7. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
[TBL] [Abstract][Full Text] [Related]
8. Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.
Rakaee M; Andersen S; Giannikou K; Paulsen EE; Kilvaer TK; Busund LR; Berg T; Richardsen E; Lombardi AP; Adib E; Pedersen MI; Tafavvoghi M; Wahl SGF; Petersen RH; Bondgaard AL; Yde CW; Baudet C; Licht P; Lund-Iversen M; Grønberg BH; Fjellbirkeland L; Helland Å; Pøhl M; Kwiatkowski DJ; Donnem T
Ann Oncol; 2023 Jul; 34(7):578-588. PubMed ID: 37100205
[TBL] [Abstract][Full Text] [Related]
9. The Genomic Landscape of
Schoenfeld AJ; Bandlamudi C; Lavery JA; Montecalvo J; Namakydoust A; Rizvi H; Egger J; Concepcion CP; Paul S; Arcila ME; Daneshbod Y; Chang J; Sauter JL; Beras A; Ladanyi M; Jacks T; Rudin CM; Taylor BS; Donoghue MTA; Heller G; Hellmann MD; Rekhtman N; Riely GJ
Clin Cancer Res; 2020 Nov; 26(21):5701-5708. PubMed ID: 32709715
[TBL] [Abstract][Full Text] [Related]
10. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.
Best SA; Gubser PM; Sethumadhavan S; Kersbergen A; Negrón Abril YL; Goldford J; Sellers K; Abeysekera W; Garnham AL; McDonald JA; Weeden CE; Anderson D; Pirman D; Roddy TP; Creek DJ; Kallies A; Kingsbury G; Sutherland KD
Cell Metab; 2022 Jun; 34(6):874-887.e6. PubMed ID: 35504291
[TBL] [Abstract][Full Text] [Related]
11. Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.
Cheng W; Xu B; Zhang H; Fang S
Thorac Cancer; 2021 Sep; 12(18):2458-2467. PubMed ID: 34328274
[TBL] [Abstract][Full Text] [Related]
12. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Zavitsanou AM; Pillai R; Hao Y; Wu WL; Bartnicki E; Karakousi T; Rajalingam S; Herrera A; Karatza A; Rashidfarrokhi A; Solis S; Ciampricotti M; Yeaton AH; Ivanova E; Wohlhieter CA; Buus TB; Hayashi M; Karadal-Ferrena B; Pass HI; Poirier JT; Rudin CM; Wong KK; Moreira AL; Khanna KM; Tsirigos A; Papagiannakopoulos T; Koralov SB
Cell Rep; 2023 Nov; 42(11):113295. PubMed ID: 37889752
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide analyses reveal the contribution of somatic variants to the immune landscape of multiple cancer types.
Bi W; Xu Z; Liu F; Xie Z; Liu H; Zhu X; Zhong W; Zhang P; Tang X
PLoS Genet; 2024 Jan; 20(1):e1011134. PubMed ID: 38241355
[TBL] [Abstract][Full Text] [Related]
14. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
15. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
Singh A; Daemen A; Nickles D; Jeon SM; Foreman O; Sudini K; Gnad F; Lajoie S; Gour N; Mitzner W; Chatterjee S; Choi EJ; Ravishankar B; Rappaport A; Patil N; McCleland M; Johnson L; Acquaah-Mensah G; Gabrielson E; Biswal S; Hatzivassiliou G
Clin Cancer Res; 2021 Feb; 27(3):877-888. PubMed ID: 33077574
[TBL] [Abstract][Full Text] [Related]
16. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
[TBL] [Abstract][Full Text] [Related]
18. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
20. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
